ANALYTICAL AND PROSPECTIVE EVALUATION OF URINARY CYTOKERATIN 19 FRAGMENT IN BLADDER CANCER
- 1 April 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 163 (4) , 1116-1119
- https://doi.org/10.1016/s0022-5347(05)67705-1
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary BladderThe American Journal of Surgical Pathology, 1998
- EVALUATION OF NMP22 IN THE DETECTION OF TRANSITIONAL CELL CARCINOMA OF THE BLADDERJournal of Urology, 1998
- Initial Evaluation of Cyfra 21-1 Diagnostic Performances as a Urinary Marker in Bladder Transitional Cell CarcinomaJournal of Urology, 1997
- Cytokeratin 20 as an objective marker of urothelial dysplasiaBritish Journal of Urology, 1996
- Clinical evaluation of soluble cytokeratin 19 fragments (cyfra 21-1) in serum and urine of patients with bladder cancerUrology, 1996
- Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical TreatmentJournal of Urology, 1996
- Clinical Evaluation of Cell Deoxyribonucleic Acid Content Measured by Flow Cytometry in Bladder CancerJournal of Urology, 1996
- Results of a Multicenter Trial using the BTA Test to Monitor for and Diagnose Recurrent Bladder CancerJournal of Urology, 1995
- Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancerEuropean Respiratory Journal, 1995
- The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cellsPublished by Elsevier ,1982